| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 30 | 2024 | 484 | 5.290 |
Why?
|
| Simian Immunodeficiency Virus | 23 | 2024 | 99 | 3.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 23 | 2023 | 503 | 2.650 |
Why?
|
| HIV Infections | 22 | 2024 | 2063 | 2.160 |
Why?
|
| Virus Replication | 23 | 2020 | 636 | 1.820 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 18 | 2024 | 75 | 1.710 |
Why?
|
| Single-Chain Antibodies | 3 | 2023 | 45 | 1.450 |
Why?
|
| HIV Antibodies | 6 | 2023 | 71 | 1.080 |
Why?
|
| Anti-HIV Agents | 4 | 2024 | 352 | 1.050 |
Why?
|
| Host-Pathogen Interactions | 4 | 2019 | 263 | 0.950 |
Why?
|
| Macaca nemestrina | 13 | 2013 | 17 | 0.920 |
Why?
|
| Deoxyadenosines | 2 | 2024 | 9 | 0.910 |
Why?
|
| Lectins, C-Type | 5 | 2007 | 73 | 0.770 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 129 | 0.770 |
Why?
|
| Cell Adhesion Molecules | 5 | 2007 | 234 | 0.730 |
Why?
|
| Cell Line | 21 | 2023 | 2730 | 0.710 |
Why?
|
| Dendritic Cells | 5 | 2010 | 448 | 0.670 |
Why?
|
| Receptors, Cell Surface | 5 | 2007 | 452 | 0.670 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 2 | 2018 | 12 | 0.650 |
Why?
|
| Leukocytes, Mononuclear | 9 | 2023 | 356 | 0.610 |
Why?
|
| GPI-Linked Proteins | 3 | 2018 | 107 | 0.600 |
Why?
|
| Spike Glycoprotein, Coronavirus | 5 | 2024 | 205 | 0.580 |
Why?
|
| Viral Tropism | 3 | 2018 | 53 | 0.570 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1759 | 0.560 |
Why?
|
| HIV | 2 | 2016 | 190 | 0.550 |
Why?
|
| Prostate | 3 | 2020 | 437 | 0.540 |
Why?
|
| Virus Latency | 2 | 2022 | 63 | 0.530 |
Why?
|
| Antigens, CD | 5 | 2015 | 437 | 0.490 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 365 | 0.480 |
Why?
|
| RNA-Directed DNA Polymerase | 3 | 2019 | 39 | 0.480 |
Why?
|
| RNA, Viral | 5 | 2020 | 566 | 0.480 |
Why?
|
| Virus Internalization | 5 | 2018 | 60 | 0.470 |
Why?
|
| Receptors, CCR5 | 5 | 2016 | 31 | 0.450 |
Why?
|
| Animals | 43 | 2024 | 34996 | 0.450 |
Why?
|
| Macaca | 9 | 2023 | 62 | 0.440 |
Why?
|
| Human T-lymphotropic virus 1 | 5 | 1995 | 64 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 1556 | 0.420 |
Why?
|
| Genetic Variation | 8 | 2008 | 1583 | 0.420 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 236 | 0.400 |
Why?
|
| Lymphocyte Activation | 6 | 2018 | 686 | 0.400 |
Why?
|
| Virulence Factors | 2 | 2012 | 187 | 0.390 |
Why?
|
| Cell Cycle | 1 | 2015 | 611 | 0.390 |
Why?
|
| Xenotropic murine leukemia virus-related virus | 1 | 2012 | 2 | 0.380 |
Why?
|
| Drug Resistance, Viral | 4 | 2024 | 50 | 0.380 |
Why?
|
| Transduction, Genetic | 4 | 2024 | 294 | 0.370 |
Why?
|
| Molecular Sequence Data | 15 | 2011 | 3780 | 0.350 |
Why?
|
| Interferon-alpha | 1 | 2013 | 246 | 0.350 |
Why?
|
| Gene Products, vif | 1 | 2011 | 7 | 0.350 |
Why?
|
| Leukemia Virus, Murine | 1 | 2010 | 4 | 0.340 |
Why?
|
| Retroviridae Infections | 1 | 2010 | 10 | 0.340 |
Why?
|
| Proviruses | 1 | 2010 | 18 | 0.340 |
Why?
|
| Viral Load | 5 | 2016 | 410 | 0.340 |
Why?
|
| Immunotherapy | 1 | 2016 | 748 | 0.340 |
Why?
|
| Antibodies, Viral | 10 | 2024 | 1205 | 0.340 |
Why?
|
| Recombination, Genetic | 2 | 2011 | 442 | 0.340 |
Why?
|
| Genetic Vectors | 4 | 2024 | 927 | 0.340 |
Why?
|
| Humans | 61 | 2024 | 132373 | 0.330 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 140 | 0.320 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 239 | 0.300 |
Why?
|
| Antibodies, Neutralizing | 7 | 2023 | 501 | 0.290 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2024 | 18 | 0.280 |
Why?
|
| Hepatitis C | 1 | 2012 | 388 | 0.280 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2024 | 38 | 0.280 |
Why?
|
| Zika Virus | 2 | 2020 | 151 | 0.270 |
Why?
|
| Amino Acid Sequence | 11 | 2010 | 2673 | 0.270 |
Why?
|
| Glycosylphosphatidylinositols | 4 | 2016 | 16 | 0.260 |
Why?
|
| Alleles | 2 | 2010 | 1683 | 0.250 |
Why?
|
| Cells, Cultured | 12 | 2018 | 3062 | 0.250 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2007 | 309 | 0.250 |
Why?
|
| Lentivirus | 2 | 2016 | 82 | 0.240 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2023 | 417 | 0.230 |
Why?
|
| Immunity, Innate | 3 | 2020 | 414 | 0.220 |
Why?
|
| Lentivirus Infections | 1 | 2024 | 3 | 0.220 |
Why?
|
| Macrophages | 5 | 2012 | 693 | 0.220 |
Why?
|
| Lamivudine | 1 | 2024 | 28 | 0.210 |
Why?
|
| Virus Integration | 3 | 2016 | 39 | 0.210 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2015 | 39 | 0.210 |
Why?
|
| Mutation | 5 | 2024 | 6250 | 0.210 |
Why?
|
| Recombinant Proteins | 6 | 2023 | 1357 | 0.200 |
Why?
|
| HIV Integrase | 1 | 2022 | 4 | 0.200 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2022 | 12 | 0.190 |
Why?
|
| Viruses | 1 | 2024 | 126 | 0.190 |
Why?
|
| HEK293 Cells | 4 | 2024 | 796 | 0.190 |
Why?
|
| CD4 Antigens | 1 | 2002 | 56 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 2 | 2023 | 153 | 0.190 |
Why?
|
| Viral Envelope Proteins | 4 | 2010 | 155 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 105 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2014 | 4695 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 1577 | 0.180 |
Why?
|
| Zika Virus Infection | 2 | 2020 | 175 | 0.180 |
Why?
|
| Genes, gag | 2 | 1998 | 8 | 0.180 |
Why?
|
| Receptors, CXCR3 | 1 | 2020 | 23 | 0.170 |
Why?
|
| Chemokine CXCL10 | 1 | 2020 | 53 | 0.170 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 219 | 0.170 |
Why?
|
| Down-Regulation | 1 | 2002 | 679 | 0.160 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 17 | 0.160 |
Why?
|
| Lentiviruses, Primate | 1 | 2019 | 1 | 0.160 |
Why?
|
| Deoxyribonucleotides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Autophagy | 3 | 2022 | 428 | 0.160 |
Why?
|
| Rectum | 1 | 2020 | 114 | 0.150 |
Why?
|
| Antigenic Variation | 1 | 1999 | 42 | 0.150 |
Why?
|
| Macaca mulatta | 5 | 2023 | 506 | 0.150 |
Why?
|
| Vaccines | 1 | 2024 | 381 | 0.150 |
Why?
|
| Genes, env | 2 | 1997 | 9 | 0.150 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 123 | 0.150 |
Why?
|
| Gene Expression | 2 | 2021 | 1564 | 0.150 |
Why?
|
| Receptors, Virus | 1 | 1999 | 110 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 803 | 0.140 |
Why?
|
| Interleukin-2 | 3 | 1998 | 241 | 0.140 |
Why?
|
| AIDS Vaccines | 1 | 2018 | 30 | 0.140 |
Why?
|
| Complement Factor I | 1 | 2017 | 1 | 0.140 |
Why?
|
| Complement C4b | 1 | 2017 | 5 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 351 | 0.130 |
Why?
|
| Camelids, New World | 1 | 2016 | 4 | 0.130 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2016 | 7 | 0.130 |
Why?
|
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2015 | 5 | 0.120 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 12 | 0.120 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2015 | 26 | 0.120 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2015 | 32 | 0.120 |
Why?
|
| Cyclin T | 1 | 2015 | 33 | 0.120 |
Why?
|
| Granzymes | 2 | 2014 | 48 | 0.120 |
Why?
|
| Recombinases | 1 | 2015 | 26 | 0.120 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2014 | 6 | 0.110 |
Why?
|
| Cyclins | 1 | 2015 | 100 | 0.110 |
Why?
|
| HeLa Cells | 2 | 2015 | 732 | 0.110 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1994 | 133 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 272 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 180 | 0.110 |
Why?
|
| CD3 Complex | 1 | 1994 | 92 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 169 | 0.110 |
Why?
|
| Kinetics | 4 | 2019 | 1179 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2012 | 492 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2018 | 903 | 0.100 |
Why?
|
| Mice | 9 | 2022 | 18572 | 0.100 |
Why?
|
| Jurkat Cells | 2 | 2007 | 86 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2011 | 1807 | 0.100 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2012 | 2 | 0.100 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2016 | 51 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1297 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2016 | 799 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2010 | 617 | 0.090 |
Why?
|
| Retroviridae Proteins | 2 | 2007 | 11 | 0.090 |
Why?
|
| Blood Donors | 1 | 2012 | 61 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 4 | 1999 | 29 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 449 | 0.090 |
Why?
|
| Glycopeptides | 1 | 2011 | 28 | 0.090 |
Why?
|
| Carrier Proteins | 1 | 2016 | 1049 | 0.090 |
Why?
|
| Disease Progression | 3 | 2024 | 2228 | 0.080 |
Why?
|
| Binding Sites | 2 | 2004 | 1255 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 701 | 0.080 |
Why?
|
| Neutralization Tests | 3 | 2024 | 237 | 0.080 |
Why?
|
| Protein Domains | 2 | 2021 | 260 | 0.080 |
Why?
|
| Virulence | 1 | 2010 | 279 | 0.080 |
Why?
|
| Endoribonucleases | 1 | 2010 | 85 | 0.080 |
Why?
|
| Gene Products, env | 3 | 2007 | 17 | 0.080 |
Why?
|
| Chimera | 3 | 1998 | 84 | 0.080 |
Why?
|
| HTLV-I Antibodies | 1 | 1989 | 3 | 0.080 |
Why?
|
| Cloning, Molecular | 3 | 2011 | 813 | 0.080 |
Why?
|
| Lymph Nodes | 3 | 2006 | 388 | 0.080 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 1989 | 31 | 0.080 |
Why?
|
| Genotype | 2 | 2017 | 2706 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 114 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2010 | 751 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 1993 | 2687 | 0.070 |
Why?
|
| SAIDS Vaccines | 1 | 2007 | 11 | 0.070 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 804 | 0.070 |
Why?
|
| Animals, Newborn | 1 | 2011 | 1035 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 125 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1598 | 0.070 |
Why?
|
| Viremia | 1 | 2007 | 133 | 0.060 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2006 | 33 | 0.060 |
Why?
|
| Male | 9 | 2023 | 65072 | 0.060 |
Why?
|
| Base Sequence | 4 | 2014 | 2904 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2012 | 527 | 0.060 |
Why?
|
| Haplorhini | 2 | 2020 | 117 | 0.060 |
Why?
|
| Genes | 1 | 2006 | 314 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2015 | 2494 | 0.060 |
Why?
|
| Adult | 6 | 2021 | 31624 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2001 | 652 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 3 | 2012 | 1038 | 0.050 |
Why?
|
| Apoptosis | 2 | 2022 | 1904 | 0.050 |
Why?
|
| CD2 Antigens | 2 | 1994 | 8 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1994 | 38 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2004 | 590 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2004 | 239 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 171 | 0.050 |
Why?
|
| Gene Products, gag | 2 | 2007 | 19 | 0.050 |
Why?
|
| Membrane Microdomains | 2 | 2016 | 61 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 1994 | 127 | 0.050 |
Why?
|
| Immunity | 1 | 2024 | 184 | 0.050 |
Why?
|
| DNA | 2 | 2006 | 1484 | 0.050 |
Why?
|
| Feedback | 1 | 2024 | 167 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 142 | 0.050 |
Why?
|
| Raltegravir Potassium | 1 | 2022 | 2 | 0.050 |
Why?
|
| Pyrrolidinones | 1 | 2022 | 19 | 0.050 |
Why?
|
| Gene Products, nef | 1 | 2002 | 17 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 69 | 0.050 |
Why?
|
| Alum Compounds | 1 | 2022 | 42 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2022 | 19 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2022 | 180 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 1052 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 226 | 0.050 |
Why?
|
| Lectins | 1 | 2001 | 49 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2022 | 111 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 128 | 0.050 |
Why?
|
| Virus Activation | 1 | 2022 | 85 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2018 | 806 | 0.040 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.040 |
Why?
|
| Saccharomycetales | 1 | 2021 | 38 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2010 | 5153 | 0.040 |
Why?
|
| Monocytes | 2 | 2006 | 345 | 0.040 |
Why?
|
| Allergists | 1 | 2020 | 7 | 0.040 |
Why?
|
| Genes, Viral | 2 | 1998 | 181 | 0.040 |
Why?
|
| Organophosphates | 1 | 2020 | 21 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 109 | 0.040 |
Why?
|
| Female | 7 | 2023 | 70809 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2020 | 60 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 64 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 75 | 0.040 |
Why?
|
| RNA Transport | 1 | 2019 | 9 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 672 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2022 | 454 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3358 | 0.040 |
Why?
|
| Triazoles | 1 | 2020 | 147 | 0.040 |
Why?
|
| Karyopherins | 1 | 2019 | 39 | 0.040 |
Why?
|
| Models, Immunological | 1 | 1999 | 37 | 0.040 |
Why?
|
| Primates | 1 | 2019 | 85 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 248 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2019 | 270 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2020 | 138 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 254 | 0.040 |
Why?
|
| Protein Transport | 1 | 2019 | 370 | 0.040 |
Why?
|
| Cell Survival | 1 | 2020 | 869 | 0.040 |
Why?
|
| Genes, pol | 1 | 1998 | 10 | 0.040 |
Why?
|
| Acute Disease | 2 | 2020 | 1176 | 0.040 |
Why?
|
| Americas | 1 | 2018 | 52 | 0.040 |
Why?
|
| Virus Cultivation | 1 | 2018 | 76 | 0.030 |
Why?
|
| HLA-B Antigens | 1 | 2017 | 30 | 0.030 |
Why?
|
| Giant Cells | 1 | 1997 | 35 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 825 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 326 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2016 | 66 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 596 | 0.030 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 50 | 0.030 |
Why?
|
| Antibody Formation | 2 | 2008 | 274 | 0.030 |
Why?
|
| Transfection | 2 | 1998 | 999 | 0.030 |
Why?
|
| DNA Primers | 1 | 1997 | 637 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2018 | 329 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1998 | 867 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 292 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 830 | 0.030 |
Why?
|
| Models, Genetic | 1 | 1999 | 771 | 0.030 |
Why?
|
| Lymphocytes | 1 | 1997 | 365 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 1047 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 544 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 1735 | 0.030 |
Why?
|
| Genes, pX | 1 | 1995 | 4 | 0.030 |
Why?
|
| Leukemia, Experimental | 1 | 1995 | 16 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2018 | 596 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2015 | 30 | 0.030 |
Why?
|
| United States | 1 | 2010 | 11631 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 1994 | 10 | 0.030 |
Why?
|
| Stem Cells | 1 | 2020 | 732 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 59 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 89 | 0.030 |
Why?
|
| Evolution, Molecular | 2 | 2008 | 698 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 91 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 378 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2014 | 164 | 0.030 |
Why?
|
| CD58 Antigens | 1 | 1993 | 7 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2014 | 98 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2014 | 159 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2512 | 0.030 |
Why?
|
| Gene Products, tax | 1 | 1993 | 47 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 343 | 0.020 |
Why?
|
| Reverse Transcription | 1 | 2012 | 5 | 0.020 |
Why?
|
| Middle Aged | 4 | 2020 | 28895 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2010 | 17371 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2446 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 92 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 117 | 0.020 |
Why?
|
| Cell Division | 1 | 1993 | 744 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 215 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 1991 | 98 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1993 | 421 | 0.020 |
Why?
|
| Fetal Blood | 1 | 1991 | 174 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2010 | 201 | 0.020 |
Why?
|
| Myristic Acids | 1 | 1989 | 7 | 0.020 |
Why?
|
| Moloney murine leukemia virus | 1 | 1989 | 18 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2014 | 720 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 764 | 0.020 |
Why?
|
| Hawaii | 1 | 1989 | 7 | 0.020 |
Why?
|
| Epitopes | 1 | 2010 | 437 | 0.020 |
Why?
|
| Deltaretrovirus Infections | 1 | 1988 | 8 | 0.020 |
Why?
|
| Glycosylation | 1 | 2008 | 126 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 4725 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 761 | 0.020 |
Why?
|
| Gene Products, pol | 1 | 2007 | 5 | 0.020 |
Why?
|
| Selection, Genetic | 1 | 2008 | 165 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2008 | 204 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2007 | 344 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2007 | 322 | 0.020 |
Why?
|
| Phylogeny | 1 | 2008 | 767 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 9949 | 0.010 |
Why?
|
| Spleen | 1 | 2006 | 275 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 21386 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2006 | 288 | 0.010 |
Why?
|
| Leukemia | 1 | 1988 | 373 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2007 | 539 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1292 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 482 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 2001 | 83 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2001 | 21 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 2001 | 56 | 0.010 |
Why?
|
| Time Factors | 1 | 1991 | 6457 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 688 | 0.010 |
Why?
|
| Genome, Human | 1 | 2006 | 1332 | 0.010 |
Why?
|
| RNA | 1 | 2001 | 549 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1989 | 7112 | 0.010 |
Why?
|
| DNA Probes | 1 | 1995 | 124 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 41 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 1995 | 189 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1995 | 1294 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 1995 | 2453 | 0.000 |
Why?
|
| Transfusion Reaction | 1 | 1988 | 39 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 4545 | 0.000 |
Why?
|